Cardium Therapeutics (NYSE MKT: CXM), an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization, recently reported continuing progress during its third quarter, including heightened awareness of Excellagen and the